甲状腺乳头状癌中PD-L1蛋白表达与BRAF V600E基因突变的相关性

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1323 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the correlation between PD-L1 protein expression and BRAF V600E gene mutation in papillary thyroid carcinoma (PTC). Methods: 74 cases of PTC and normal thyroid tissue specimens were used to detect PD-L1 protein expression by immunohistochemical EnVision two step method. Gene mutation of BRAF V600E was detected by Q-PCR. And the correlation between PD-L1 protein expression and the clinicopathological parameters of PTC including BRAF V600E gene mutation was evaluated. Results: The positive rate of PD-L1 protein expression was 48.6% (36/74) in PTC tissues, significantly higher than that in control group (P<0.01). The expression of PD-L1 protein was correlated with age, tumor size, chronic lymphocytic thyroiditis (CLT) background, tumor-infiltrating lymphocytes (TILs) and clinical stage (P<0.05). The positive rate of BRAF V600E gene mutation was 79.7% (59/74) in PTC tissues. The gene mutation of BRAF V600E was correlated with histological classification of PTC (P<0.01). Consistency analysis showed that there was no relationship between PD-L1 protein expression and BRAF V600E gene mutation (Kappa=-0.091, P>0.05). Among these parameters, background CLT was independent factor affecting PD-L1 protein expression (OR=18.675, 95%CI: 3.074~113.453, P<0.01). Conclusion: PD-L1 protein is over-expressed in PTC tissues. The expression of PD-L1 protein is correlated with clinicopathologic features of PTC, but there is no relationship between PD-L1 protein expression and BRAF V600E gene mutation in PTC.

Key words： papillary thyroid carcinoma PD-L1 BRAF V600E gene mutation

Received: 05 April 2018

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LUO Huarong
	GAN Meifu
	XU Cheng
	XU Weiming
	LIANG Yong

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2018/V48/I10/718

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30.
[2] CUNHA L L, MARCELLO M A, MORARI E C, et al. Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation[J]. Endocr Relat Cancer, 2013, 20(1): 103-110.
[3] XING M. BRAF mutation in thyroid cancer[J]. Endocr Relat Cancer, 2005, 12(2): 245-262.
[4] 孙威, 贺亮, 张浩. 美国癌症联合委员会甲状腺癌分期系统(第8版)更新解读[J]. 中国实用外科杂志, 2017, 37(3): 255-258.
[5] SALGADO R, DENKERT C, DEMARIA S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014[J]. Ann Oncol, 2015, 26(2): 259-271.
[6] BAI Y, NIU D, HUANG X, et al. PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma[J]. Diagn Pathol, 2017, 12(1): 72-79.
[7] SHARMA P, ALLISON J P. The future of immune checkpoint therapy[J]. Science, 2015, 348(6230): 56-61.
[8] SCOGNAMIGLIO G, DE CHIARA A, DI BONITO M, et al.
Variability in immunohistochemical detection of programmed death ligand 1 (PD-L1) in cancer tissue types[J]. Int J Mol Sci, 2016, 17(12): 790-800.
[9] CHOWDHURY S, VEYHL J, JESSA F, et al. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants[J]. Oncotarget, 2016, 7(22): 32318-32328.
[10] HAYASHI M, KOUKI T, TAKASU N, et al. Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves’ disease in Japanese pa-tients[J]. Eur J Endocrinol, 2008, 158(6): 817-822.
[11] SHARMA P, ALLISON J P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential[J]. Cell, 2015, 161(2): 205-214.
[12] TENG M W, NGIOW S F, RIBAS A, et al. Classifying cancers based on T-cell infiltration and PD-L1[J]. Cancer Res, 2015, 75(11): 2139-2145.
[13] GANLY I, NIXON I J, WANG L Y, et al. Survival from differentiated thyroid cancer: What has age got to do with it? [J]. Thyroid, 2015, 25(10): 1106-1114.
[14] NIXON I J, KUK D, WREESMANN V, et al. Defining a valid age cutoff in staging of well-differentiated thyroid can-cer[J]. Ann Surg Oncol, 2016, 23(2): 410-415.
[15] XING M, ALZAHRANI A S, CARSON K A, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer[J]. JAMA, 2013, 309(14): 1493-1501.
[16] LEE J H, LEE E S, KIM Y S. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid[J]. Cancer, 2007, 110(1): 38-46.
[17] ANGELL T E, LECHNER M G, JANG J K, et al. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration[J]. Thyroid , 2014, 24(9): 1385-1393.
[18] BASTMAN J J, SERRACINO H S, ZHU Y, et al. Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer[J]. J Clin Endocrinol Metab, 2016, 101(7): 2863-2873.